Schistosomiasis is an important tropical parasitic human disease. Although an effective anti-schistosome drug is in use, it is estimated that 200 million people remain infected, 20 million individuals suffer severe disease symptoms, and 280,000 people die annually from schistosomiasis. Furthermore, transmission rates have changed a little with the use of the drug and there is evidence for the development of drug resistant parasites. Because there is currently no suitable alternative therapy available there is an urgent need for the development of novel antischistosomal agents. In this application we propose to focus on parasite biochemical redox mechanisms as novel targets for antischistosomal drug development. Schistosomes in their definitive and intermediate hosts must be able to survive in the presence of both immune and self generated reactive oxygen compounds and provide disulfide reducing equivalents for a number of critical enzymatic pathways. Two parallel systems to provide oxidative defense and reducing power occur in most organisms, one based on glutathione and the other based on thioredoxin. Our recent results indicate that Schistosoma mansoni has fundamentally different redox mechanisms from their mammalian host. Entirely absent from worms are two key redox enzymes, glutathione reductase and thioredoxin reductase. Instead, these activities are found together in a single protein thioredoxin-glutathione reductase (TGR). We have shown that TGR is an essential parasite protein and that inhibition of the TGR leads to parasite death. In the research proposal we will: (1) synthesize potential TGR inhibitors based on lead compounds we have already identified and determine their relative inhibitory activity against parasite and host enzymes and their toxicity to cultured worms and mammalian cells, (2) develop an hypothesis for the catalytic mechanism of TGR, which will further the development of TGR inhibitors and, (3) define conditions suitable for the crystallization of TGR and determine its 3D structure for drug refinement. Because disulfide redox balance in schistosomes is centered on a single key redox enzyme and is fundamentally different from host mechanisms we propose in exploit this parasite pathway as a promising target for rational drug design. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI065622-03
Application #
7774813
Study Section
Pathogenic Eukaryotes Study Section (PTHE)
Program Officer
Rogers, Martin J
Project Start
2007-04-15
Project End
2012-03-31
Budget Start
2008-08-01
Budget End
2009-03-31
Support Year
3
Fiscal Year
2008
Total Cost
$188,237
Indirect Cost
Name
Rush University Medical Center
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Bielitza, Max; Belorgey, Didier; Ehrhardt, Katharina et al. (2015) Antimalarial NADPH-Consuming Redox-Cyclers As Superior Glucose-6-Phosphate Dehydrogenase Deficiency Copycats. Antioxid Redox Signal 22:1337-51
Johann, Laure; Belorgey, Didier; Huang, Hsin-Hung et al. (2015) Synthesis and evaluation of 1,4-naphthoquinone ether derivatives as SmTGR inhibitors and new anti-schistosomal drugs. FEBS J 282:3199-217
Guglielmo, Stefano; Cortese, Daniela; Vottero, Francesca et al. (2014) New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni. Eur J Med Chem 84:135-45
Ziniel, Peter D; Desai, Janish; Cass, Cynthia L et al. (2013) Characterization of potential drug targets farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase in Schistosoma mansoni. Antimicrob Agents Chemother 57:5969-76
Belorgey, Didier; Lanfranchi, Don Antoine; Davioud-Charvet, Elisabeth (2013) 1,4-naphthoquinones and other NADPH-dependent glutathione reductase-catalyzed redox cyclers as antimalarial agents. Curr Pharm Des 19:2512-28
Williams, David L; Bonilla, Mariana; Gladyshev, Vadim N et al. (2013) Thioredoxin glutathione reductase-dependent redox networks in platyhelminth parasites. Antioxid Redox Signal 19:735-45
Huang, Hsin-Hung; Rigouin, Coraline; Williams, David L (2012) The redox biology of schistosome parasites and applications for drug development. Curr Pharm Des 18:3595-611
Mott, Bryan T; Cheng, Ken Chih-Chien; Guha, Rajarshi et al. (2012) A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases(). Medchemcomm 3:1505-1511
Johann, Laure; Lanfranchi, Don Antoine; Davioud-Charvet, Elisabeth et al. (2012) A physico-biochemical study on potential redox-cyclers as antimalarial and anti-schistosomal drugs. Curr Pharm Des 18:3539-66
Lanfranchi, Don Antoine; Cesar-Rodo, Elena; Bertrand, BenoƮt et al. (2012) Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents. Org Biomol Chem 10:6375-87

Showing the most recent 10 out of 21 publications